GNLY (E3N1M) Rabbit mAb #24253
- WB
- IF
- F
Supporting Data
| REACTIVITY | H |
| SENSITIVITY | Endogenous |
| MW (kDa) | 13-15 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
- IF-Immunofluorescence
- F-Flow Cytometry
Species Cross-Reactivity Key:
- H-Human
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunofluorescence (Immunocytochemistry) | 1:800 - 1:1600 |
| Flow Cytometry (Fixed/Permeabilized) | 1:100 - 1:400 |
Storage
Protocol
Specificity / Sensitivity
GNLY (E3N1M) Rabbit mAb recognizes endogenous levels of both long and short isoforms of human GNLY protein.
Species Reactivity:
Human
Source / Purification
Monoclonal antibody is produced by immunizing animals with recombinant human GNLY protein.
Background
Granulysin (GNLY) was originally identified as a late activation marker in T cells, and it is expressed by killer lymphocytes in most mammals, but not rodents. GNLY is largely confined to cytotoxic granules but can be secreted by killer cells, especially those expressing high levels of GNLY, such as decidual natural killer (NK) cells (1-3). GNLY is produced as a 15 kDa protein and is processed into a 9 kDa active pore-forming fragment by proteolytic removal of peptides from both the N- and C-termini. Moreover, the 15 kDa form was reported to function as an immune alarmin, causing the maturation and migration of antigen-presenting cells and other immune cells (4-7). Unlike perforin, a cholesterol-dependent pore-forming protein that preferentially permeabilizes mammalian membranes, GNLY is inhibited by cholesterol and forms pores much more efficiently in microbial than mammalian membranes, and it plays an important role against bacteria, fungi, and parasite infections (8,9).
- Jongstra, J. et al. (1987) J Exp Med 165, 601-14.
- Pitabut, N. et al. (2011) Microbiol Immunol 55, 565-73.
- Crespo, Â.C. et al. (2020) Cell 182, 1125-1139.e18.
- Hanson, D.A. et al. (1999) Mol Immunol 36, 413-22.
- Tewary, P. et al. (2010) Blood 116, 3465-74.
- Clayberger, C. et al. (2012) J Immunol 188, 6119-26.
- Sparrow, E. and Bodman-Smith, M.D. (2020) Immunol Lett 217, 126-132.
- Kumar, J. et al. (2001) Expert Opin Investig Drugs 10, 321-9.
- Dotiwala, F. and Lieberman, J. (2019) Curr Opin Immunol 60, 19-29.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.